Use of CRISPR/Cas9 to directly engineer BRAF-inhibitor resistant melanoma cells provides a unique opportunity to study mutations associated with BRAF-inhibitor resistance in the absence of any selective drug pressure or exogenous protein expression and enable such mutant alleles to be expressed from the native promoter at physiologically relevant levels. This evidence concerns the gene BRAF and melanoma.